Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Solara Active Pharma to probe lots of Nizatidine API amid Mylan recall

      Solara Active Pharma to probe lots of Nizatidine API amid Mylan recall

      Farhat Nasim10 Jan 2020 9:25 AM IST
      "We understand from Mylan NV's press release dated January 8, 2020, that Mylan Pharmaceuticals has initiated a voluntary recall of three lots of...
      Blackstone Group secures USD 3.4 billion life sciences fund

      Blackstone Group secures USD 3.4 billion life sciences fund

      Farhat Nasim10 Jan 2020 9:15 AM IST
      Since it set up a life sciences unit, Blackstone has unveiled a joint venture with Novartis AG to develop a novel heart treatment and invested $400...
      Blueprint gets USFDA nod for cancer therapy Ayvakit

      Blueprint gets USFDA nod for cancer therapy Ayvakit

      Farhat Nasim10 Jan 2020 9:00 AM IST
      The USFDA's decision makes Blueprint Medicines' cancer therapy, Ayvakit, the first treatment for a small subset of patients with a mutation of cancer...
      DCGI to conduct Special Public Hearing every month; Details

      DCGI to conduct Special Public Hearing every month; Details

      Farhat Nasim7 Jan 2020 2:15 PM IST
      As per the order, a special hearing will be conducted at the DCGI Office every month. Every second and the fourth Wednesday, from 3 in the evening has...
      Glenmark gets USFDA nod for Deferasirox tablets to treat high levels of iron

      Glenmark gets USFDA nod for Deferasirox tablets to treat high levels of iron

      Farhat Nasim7 Jan 2020 11:55 AM IST
      "Glenmark Pharmaceuticals Inc, USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (US FDA) for...
      Drug developers including AstraZeneca, GSK take fresh aim at guided-missile cancer drugs: Report

      Drug developers including AstraZeneca, GSK take fresh aim at guided-missile cancer drugs: Report

      Farhat Nasim7 Jan 2020 9:00 AM IST
      These antibody-drug conjugates, or ADCs, from companies including AztraZeneca and GlaxoSmithKline, are described by researchers as "guided missiles"...
      Biocon sells 2.44 pc stake in Biocon Biologics worth Rs 536.25 crore to True North

      Biocon sells 2.44 pc stake in Biocon Biologics worth Rs 536.25 crore to True North

      Farhat Nasim6 Jan 2020 4:38 PM IST
      As per the terms of the proposed agreement, True North will invest Rs 536.25 crore and will eventually translate to a 2.44 per cent minority stake in...
      Sun Pharma plea to refix price of Ciprofloxacin Hydrochloride Injection rejected

      Sun Pharma plea to refix price of Ciprofloxacin Hydrochloride Injection rejected

      Farhat Nasim6 Jan 2020 1:15 PM IST
      New Delhi: In a major setback to Ranbaxy Laboratories Limited (now Sun Pharmaceutical Industries Ltd.), the Department of Pharmaceuticals (DoP) has...
      GPT Pharma Hyderabad unit red-flagged by USFDA for CGMP violations

      GPT Pharma Hyderabad unit red-flagged by USFDA for CGMP violations

      Farhat Nasim6 Jan 2020 10:54 AM IST
      In a warning letter to GPT Pharma's MD Ashok Adityan, USFDA said during inspection of the facility, its investigators observed specific violations,...
      Boehringer unveils DiaTEC, a new, proprietary purification technology for PCV2 vaccine Ingelvac CircoFLEX

      Boehringer unveils DiaTEC, a new, proprietary purification technology for PCV2 vaccine Ingelvac CircoFLEX

      Farhat Nasim6 Jan 2020 9:25 AM IST
      Eleven years after launching Ingelvac CircoFLEX, researchers of Boehringer Ingelheim developed a process, named DiaTEC, within the current outline of...
      Mumbai police to like move against Johnson and Johnson over faulty hip implants, says report

      Mumbai police to like move against Johnson and Johnson over faulty hip implants, says report

      Farhat Nasim5 Jan 2020 3:05 PM IST
      New Delhi: Johnson and Johnson (JnJ) seems to be in for aome more trouble, as the Mumbai police is about to file a formal case against JnJ's...
      Antabio gets USD 4.4 million funding to develop new treatment for Pseudomonas aeruginosa infections in CF patients

      Antabio gets USD 4.4 million funding to develop new treatment for Pseudomonas aeruginosa infections in CF patients

      Farhat Nasim5 Jan 2020 9:15 AM IST
      New Delhi: Antabio SAS, the biopharmaceutical company focused on developing a broad pipeline of antibacterial treatments against life-threatening WHO...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok